Orizal Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Orizal Plus is a fixed‑dose combination that addresses hypertension through several complementary mechanisms.

• Hypertension: helps achieve target blood pressure when single‑agent therapy is insufficient.
• Cardiovascular risk reduction: contributes to lowering the risk of stroke and myocardial infarction in patients with elevated blood pressure.
• Renal protection: assists in slowing progression of hypertensive nephropathy by providing consistent blood pressure control.

• The combination pairs an angiotensin‑II receptor blocker (olmesartan) that blocks vasoconstrictive signaling, a calcium‑channel blocker (amlodipine) that relaxes vascular smooth muscle, and a thiazide diuretic (hydrochlorothiazide) that reduces plasma volume. Together they lower systemic vascular resistance and cardiac output, producing an additive antihypertensive effect.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of the lower limbs.
• Dizziness or light‑headedness, especially after the first doses.
• Flushing: transient warmth or redness of the skin.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Electrolyte imbalance: especially low potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Angio‑edema: rapid swelling of face, lips, tongue or throat.
• Liver enzyme elevation: abnormal liver function tests.
• Blood dyscrasias: rare blood cell abnormalities.

When prescribing Orizal Plus, clinicians should consider several safety aspects.

• Renal impairment: adjust monitoring as the diuretic may affect kidney function.
• Hepatic disease: use cautiously, as amlodipine metabolism is hepatic.
• Electrolyte disturbances: monitor potassium and sodium levels regularly.
• Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockade.
• Concomitant antihypertensives: risk of additive blood‑pressure lowering effects.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Orizal Plus can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

• Aliskiren: combined use with an ARB may increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors: concurrent use can increase risk of hypotension and renal dysfunction.
• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may raise amlodipine concentrations.
• Antidiabetic agents: blood‑glucose control may be altered, requiring dose adjustment.